Pemex Use In Pregnancy & Lactation

Pregnancy: Based on its mechanism of action, Pemetrexed can cause fetal harm when administered to a pregnant woman. There are no adequate and well controlled studies of Pemetrexed in pregnant women. Pemetrexed was embryotoxic, fetotoxic, and teratogenic in mice. In mice, repeated intraperitoneal doses of Pemetrexed when given during organogenesis caused fetal malformations (incomplete ossification of talus and skull bone; about 1/833 the recommended intravenous human dose on a mg/m² basis), and cleft palate (1/33 the recommended intravenous human dose on a mg/m² basis). Embryotoxicity was characterized by increased embryo-fetal deaths and reduced litter sizes. If Pemetrexed is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to use effective contraceptive measures to prevent pregnancy during the treatment with Pemetrexed.
Nursing Mothers: It is not known whether Pemetrexed or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Pemetrexed, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug for the mother.